MGTX - Magenta Therapeutics shares positive data from multiple myeloma study

Magenta Therapeutics (NASDAQ:MGTX) disclosed positive topline data from a Phase 2 trial for MGTA-145 stem cell mobilization in multiple myeloma. The investigator-initiated study was designed with the primary endpoint of mobilization and collection of 2M CD34+ stem cells per kg in up to two days of same-day mobilization and apheresis. According to data to be presented at the 2021 American Society of Hematology (ASH) Annual Meeting, the trial has met the primary endpoint for 88% of patients (22/25) who were treated with MGTA-145 plus plerixafor. 68% of patients (17/25) reached the primary endpoint in a single day of dosing and collection. 68% (17/25) and 40% (10/25) patients met the secondary endpoint of 4M and 6M CD34+ stem cells per kg in up to two days. Magenta (MGTX) plans to start a Phase 1/2 trial for conditioning product candidate MGTA-117 in December, targeting the patients with myeloid leukemia (AML) and myelodysplastic syndromes (MDS). FDA cleared

For further details see:

Magenta Therapeutics shares positive data from multiple myeloma study